Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - Review of the literature

European Journal of Medical Research

Volumn 16, Issue 4, 2011, Pages 180-186

  Wilke, Michael ^a  

^a Dr Wilke GmbH Inspiringhealth   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANDIDA; CANDIDEMIA; CANDIDIASIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE INCREASE; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; FUNGAL DETECTION; FUNGAL STRAIN; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL COST; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; KIDNEY DISEASE; KIDNEY FAILURE; LENGTH OF STAY; LIVER TOXICITY; MORTALITY; MYCOSIS; QUALITY ADJUSTED LIFE YEAR; TREATMENT DURATION; TREATMENT OUTCOME; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; INFECTION PREVENTION; SYSTEMATIC REVIEW;

EID: 79955826015     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-16-4-180     Document Type: Article

References (44)

1. Grover ND. Echinocandins: A ray of hope in antifungal drug therapy. Indian journal of pharmacology;42:9-11.
2. Hassan I, Powell G, Sidhu M, Hart WM, Denning DW. Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009;59:360-5.
3. Hennen CR. Pharmacoeconomic evaluations of antifungal therapies. Curr Med Res Opin 2009;25:1751-8.
4. Alexander BD, Ashley ED, Reller LB, Reed SD. Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis 2006;54:277-82.
5. Al-Badriyeh D, Liew D, Stewart K, Kong DC. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. The Journal of antimicrobial chemotherapy;63:1276-85.
6. Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Annals of internal medicine;143:857-69.
7. Gagne JJ, Breitbart RE, Maio V, al e. Costs associated with candidemia in a hospital setting. Pharmacol Ther 2006;31:586-619.
8. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9.
9. Gagne JJ, Goldfarb NI. Candidemia in the in-patient setting: treatment options and economics. Expert Opin Pharmacother 2007;8:1643-50. (Pubitemid 47296549)
10. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:781-8. (Pubitemid 29244335)
11. Forrest GN, Mankes K, Jabra-Rizk MA, et al. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. Journal of clinical microbiology;44:3381-3.
12. Falci DR, Dos SRP, Wirth F, Goldani LZ. Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment. Mycoses.
13. Wingard JR, Leather HL, Wood CA, et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. American journal of health-system pharmacy : AJHP: official journal of the American Society of Health-System Pharmacists;64:637-43.
14. Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. The Journal of antimicrobial chemotherapy;65:1765-70.
15. Kaskel P, Tuschy S, Wagner A, et al. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Annals of hematology;87:311-9.
16. Zilberberg MD, Kothari S, Shorr AF. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Critical care (London, England) 2009;13:R94.
17. Earnshaw SR GC, Gasper S. Cost-effectiveness of Anidulafungin in confirmed candidemia and other forms of invasive candidiasis. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, Ill.; 2007.
18. Reboli AC RC, Kett DH, Schorr A, Hux M, Maschio M, Chambers R, Tarallo M. Economic Evaluation of anidulafungin (Eraxis(R)/ECALTA(R)) versus intravenous fluconazole in the treatment of hospital inpatients diagnosed with candidemia an other forms of invasive candidiasis (C/IC). In: 19th ECCMID. Helsinki, Finland; 2009.
19. Williams A. The role of health economics in clinical decision-making: is it ethical? Respiratory medicine;85 Suppl B:3-5.
20. Brouwer WB, Koopmanschap MA. On the economic foundations of CEA. Ladies and gentlemen, take your positions! Journal of health economics;19:439-59.
21. Schwalm A, Danner M, Seidl A, Volz F, Dintsios CM, Gerber A. Wo steht die Kosten-Nutzen-Bewertung des IQWiG : Abgleich mit einem internationalen Referenzszenario? IQWiG's methods for the cost-benefit assessment : Comparison with an international reference scenario]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz;53:615-22.
22. Brazier JE, Dixon S, Ratcliffe J. The role of patient preferences in cost-effectiveness analysis: a conflict of values? PharmacoEconomics 2009;27:705-12.
23. Wingard JR, Wood CA, Sullivan E, Berger ML, Gerth WC, Mansley EC. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin Ther 2005;27:960-9. (Pubitemid 41583535)
24. Sidhu MK, van EAK, Kleintjens J, Schoeman O, Palazzo M. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. Current medical research and opinion;25:2049-59.
25. Stam WB, Aversa F, Kumar RN, Jansen JP. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2008;11:830-41.
26. Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. European journal of haematology;78:532-9.
27. Cornely OA, Sidhu M, Odeyemi I, van EAK, van dWJM, Schoeman O. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Current medical research and opinion;24:1743-53.
28. Nomura K, Kawasugi K, Morimoto T. Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. European journal of cancer care;15:44-50.
29. Sohn HS, Lee TJ, Kim J, Kim D. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clinical therapeutics;31:1105-15; discussion 066-8.
30. Schonfeld W, Wang CJ, Tong KB, Seifeldin R. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clinical therapeutics;30:964-73.
31. Garcia. Pharmaco-economic evaluation of currently available echinocandins in a spanish hospital setting. In: 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Paris; 2009.
32. Reboli AC, Rotstein C, Kett DH, al. e. Resource utilisation and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.. Pharmacoeconomics [in press] 2011.
33. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. The New England journal of medicine;356:2472-82.
34. Vehreschild JJ, Kummerle T, Karthaus M, Cornely OA. Anidulafungin - state of affairs from a clinical perspective. Mycoses 2007;50 Suppl 1:38-43. (Pubitemid 46495989)
35. Estes KE, Penzak SR, Calis KA, Walsh TJ. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy 2009;29:17-30.
36. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93. (Pubitemid 32221925)
37. Raymond S, Henon T, Grenouillet F, et al. [Clinical audit on the use of expensive systemic antifungals in the Besancon University Hospital]. Med Mal Infect 2009;39:125-32.
38. Arnold HM, Micek ST, Shorr AF, et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010;30:361-8.
39. Wang P. Rapid differentiation of Candida albicans from non-C. albicans directly in a variety of clinical specimens using fluorescent in situ hybridisation. Mycoses.
40. Wang JL, Chang CH, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrobial agents and chemotherapy;54:2409-19.
41. Wilke MH. Multiresistant bacteria and current therapy - the economical side of the story. Eur J Med Res 2010;15:571-6.
42. Erjavec Z, Kluin-Nelemans H, Verweij PE. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect 2009;15:625-33.
43. Hosseini-Moghaddam SM, Husain S. Fungi and molds following lung transplantation. Semin Respir Crit Care Med 2010;31:222-33.
44. Playford EG, Lipman J, Sorrell TC. Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr Opin Crit Care 2010;16:470-4.